Mesothelioma - Updated Analysis in Second-Line Treatment of Lung Cancer Trial Confirms Similar Survival for Alimta(R) and Docetaxel
Updated Analysis in Second-Line Treatment of Lung Cancer Trial Confirms Similar Survival for Alimta(R) and Docetaxel
ATLANTA, June 4 /PRNewswire-FirstCall/ -- Data
Updated Analysis in Second-Line Treatment of Lung Cancer Trial Confirms Similar Survival for Alimta(R) and Docetaxel
Data presented today at the 42nd American Society of Clinical Oncology annual meeting in Atlanta, Ga., affirms that ALIMTA , manufactured and marketed by Eli Lilly and Company, offers patients with advanced non-small cell lung cancer similar overall survival as docetaxel .
CuraGen, TopoTarget start phase II trial with mesothelioma drug
CuraGen Corporation and TopoTarget A/S announced the initiation of patient dosing in a phase II clinical trial evaluating the activity of PXD101, a small molecule histone deacetylase (HDAC) inhibitor, for the treatment of mesothelioma.
Lilly Breast Cancer Studies Explore Potential Role of Pharmacogenomics in Customizing Chemotherapy
ATLANTA, June 3 /PRNewswire-FirstCall/ -- At t
